[go: up one dir, main page]

BRPI0914889A2 - peptídeo glp-1 adicionado de cadeia oligossacarídica - Google Patents

peptídeo glp-1 adicionado de cadeia oligossacarídica

Info

Publication number
BRPI0914889A2
BRPI0914889A2 BRPI0914889A BRPI0914889A BRPI0914889A2 BR PI0914889 A2 BRPI0914889 A2 BR PI0914889A2 BR PI0914889 A BRPI0914889 A BR PI0914889A BR PI0914889 A BRPI0914889 A BR PI0914889A BR PI0914889 A2 BRPI0914889 A2 BR PI0914889A2
Authority
BR
Brazil
Prior art keywords
peptide
oligosaccharide chain
chain added
added glp
glp
Prior art date
Application number
BRPI0914889A
Other languages
English (en)
Inventor
Hiroaki Asai
Izumi Sakamoto
Katsunari Tezuka
Kazuhiro Fukae
Kazuyuki Ishii
Naohiro Hayashi
Takashi Tsuji
Yasuhiro Kajihara
Yuri Nambu
Original Assignee
Otsuka Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Chemical Co Ltd filed Critical Otsuka Chemical Co Ltd
Publication of BRPI0914889A2 publication Critical patent/BRPI0914889A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0914889A 2008-06-17 2009-06-15 peptídeo glp-1 adicionado de cadeia oligossacarídica BRPI0914889A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008157583 2008-06-17
JP2008326609 2008-12-22
PCT/JP2009/002709 WO2009153960A1 (ja) 2008-06-17 2009-06-15 糖鎖付加ｇｌｐ－１ペプチド

Publications (1)

Publication Number Publication Date
BRPI0914889A2 true BRPI0914889A2 (pt) 2015-11-24

Family

ID=41433882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914889A BRPI0914889A2 (pt) 2008-06-17 2009-06-15 peptídeo glp-1 adicionado de cadeia oligossacarídica

Country Status (11)

Country Link
US (1) US8765669B2 (pt)
EP (1) EP2298801A4 (pt)
JP (1) JP5604297B2 (pt)
KR (1) KR101609005B1 (pt)
CN (1) CN102083854A (pt)
AU (1) AU2009261441B2 (pt)
BR (1) BRPI0914889A2 (pt)
CA (1) CA2727147A1 (pt)
RU (1) RU2543157C2 (pt)
TW (1) TWI459960B (pt)
WO (1) WO2009153960A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
EP2495255A4 (en) * 2009-10-30 2013-05-15 Otsuka Chemical Co Ltd GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN103930441B (zh) * 2011-09-04 2017-11-17 株式会社糖锁工学研究所 附加糖链的多肽和含有该多肽的医药组合物
SG10201601327RA (en) * 2011-09-04 2016-03-30 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012317325B2 (en) * 2011-10-01 2016-10-06 Glytech, Inc. Glycosylated polypeptide and pharmaceutical composition containing same
CA2869786A1 (en) 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising mucin-domain polypeptide linkers
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
JP6211533B2 (ja) 2012-11-22 2017-10-11 株式会社糖鎖工学研究所 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法
KR102227919B1 (ko) * 2012-11-30 2021-03-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 링커, 당쇄 부가 링커와 생리 활성 물질을 포함하는 화합물 또는 그 염, 및 그것들의 제조 방법
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
WO2014157107A1 (ja) * 2013-03-29 2014-10-02 株式会社糖鎖工学研究所 シアリル化糖鎖が付加されたポリペプチド
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
CN109021093B (zh) * 2018-08-29 2021-09-07 上海生物制品研究所有限责任公司 聚乙二醇修饰的glp-1衍生物及其药用盐
CN110713517B (zh) * 2019-10-11 2022-11-01 润辉生物技术（威海）有限公司 一种乙酰透明质酸寡肽及其制备与应用方法
CN114761412B (zh) 2019-11-25 2024-10-11 阿尔克姆斯有限公司 取代的大环化合物和相关治疗方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
EP4314073A4 (en) 2021-03-24 2025-02-19 Alkermes, Inc. Upar antibodies and fusion proteins with the same
US20240270811A1 (en) * 2021-05-13 2024-08-15 Tokyo University Of Science Foundation Glycosylated Neuropeptide Derivative, Pharmaceutical Composition, Intranasal/Nasal Drop Formulation, and Use of Pharmaceutical Composition
CN115215948B (zh) * 2022-06-02 2023-07-11 润辉生物技术（威海）有限公司 一种低分子的乙酰透明质酸脱羧肌肽衍生物、制备方法及应用
KR20250106286A (ko) * 2022-11-10 2025-07-09 갓코호우징 도쿄리카다이가쿠 신경 펩타이드 서열 및 당쇄를 포함하는 당쇄 수식 신경 펩타이드 유도체, 의약 조성물, 경비·점비 제제 및 당쇄 수식 신경 펩타이드 유도체의 사용
WO2024101434A1 (ja) * 2022-11-10 2024-05-16 学校法人東京理科大学 眼疾患の治療のための生理活性ペプチド誘導体、医薬組成物、経鼻・点鼻製剤及び生理活性ペプチド誘導体の使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
AU4116801A (en) * 2000-03-17 2001-09-24 Ajinomoto Kk Drugs for complications of diabetes and neuropathy and utilization thereof
KR100885149B1 (ko) 2001-06-19 2009-02-23 오츠카 가가쿠 가부시키가이샤 당쇄 아스파라긴 유도체의 제조 방법
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
TWI330641B (en) 2002-12-24 2010-09-21 Yasuhiro Kajihara Sugar chain asparagine derivatives
KR100661212B1 (ko) 2002-12-26 2007-04-16 오츠카 가가쿠 가부시키가이샤 3분지형 당사슬 아스파라긴 유도체, 상기 당사슬아스파라긴, 상기 당사슬 및 그들의 제조방법
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4237752B2 (ja) 2003-02-04 2009-03-11 大塚化学株式会社 糖鎖アスパラギン誘導体の製造方法
CN101798586B (zh) 2003-07-28 2013-11-06 株式会社糖锁工学研究所 糖肽的制造方法
JPWO2005095331A1 (ja) 2004-03-31 2008-02-21 塩野義製薬株式会社 糖鎖−ペプチド結合剤
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
TW200643033A (en) 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
TWI466897B (zh) 2005-07-19 2015-01-01 Glytech Inc 癌細胞之檢測方法、糖鏈之構造解析方法，以及糖鏈衍生物
EP1961764B1 (en) 2005-11-30 2011-05-11 Shionogi Co., Ltd. Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient
WO2008011446A2 (en) * 2006-07-18 2008-01-24 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
KR20100049032A (ko) * 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 당사슬 부가 ｇｌｐ―１ 펩티드

Also Published As

Publication number Publication date
KR20110031458A (ko) 2011-03-28
US8765669B2 (en) 2014-07-01
US20110195897A1 (en) 2011-08-11
AU2009261441B2 (en) 2013-01-10
CN102083854A (zh) 2011-06-01
WO2009153960A1 (ja) 2009-12-23
EP2298801A4 (en) 2011-08-03
TWI459960B (zh) 2014-11-11
RU2543157C2 (ru) 2015-02-27
JP5604297B2 (ja) 2014-10-08
AU2009261441A1 (en) 2009-12-23
KR101609005B1 (ko) 2016-04-04
CA2727147A1 (en) 2009-12-23
TW201004643A (en) 2010-02-01
EP2298801A1 (en) 2011-03-23
RU2011101464A (ru) 2012-07-27
JPWO2009153960A1 (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
BRPI0914889A2 (pt) peptídeo glp-1 adicionado de cadeia oligossacarídica
ATE554786T1 (de) Pegylierte insulin-lispro-verbindungen
DE602009000328D1 (de) Parallelmechanismus
EP3450425C0 (en) PERCARBOXYLIC ACID COMPOSITION
LU92600I2 (fr) Sovaldi (sofosbuvir)
BRPI0905874A2 (pt) Composição fotoprotetora
DK2370461T3 (da) Glucagonanaloger
DE602008003047D1 (de) Heckleuchtenstruktur
DE602006021235D1 (de) Kristallglasgegenstand
DK1849352T3 (da) Mejetærsker
EP2303730A4 (en) SWINGING FEEDER
BRPI0918602A2 (pt) composto (i)
BRPI0908346A2 (pt) beteria
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI0913321A2 (pt) transportador de peça
EP2236266A4 (en) Injector
BRPI0915562A2 (pt) tamis melhorado
BRPI0915442A2 (pt) tamis melhorado
DK2278899T3 (da) Bryggemekanisme
FI20070937A0 (fi) Perhekeinu
DE502007006202D1 (de) Kämmmaschine
BRPI0922477A2 (pt) transportador.
DE502007002482D1 (de) Injektor
DE502006007770D1 (de) Transportgeschirrspülmaschine
AT504336B8 (de) Kettenrad

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GLYTECH, INC. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL